|MDACC Study No:||2009-0583 (clinicaltrials.gov NCT No: NCT01014936)|
|Title:||A Phase I Open-Label, Non-Randomized, Dose-Escalation|
First-in-Man Trial to Investigate the c-Met Kinase Inhibitor
MSC2156119J Under Three Different Regimens in Subjects
with Advanced Solid Tumors
|Principal Investigator:||David S. Hong|
|Study Description:||The goal of this clinical research study is to find a dose and schedule of |
MSC2156119J (also known as EMD 1214063) ("study drug") that can be safely given
to patients with advanced solid cancer.
How well the study drug works in the treatment of cancer will also be studied.